Tirzepatide: Two for One Efficacy? Diabetes + Obesity?
December 10, 2020 — News from Eli Lilly and Company suggests that we may soon see a new drug that offers two-for-one efficacy – a clinical benefit in both obesity and diabetes. The company announced yesterday that tirzepatide produced good results against endpoints for both diseases in a phase 3 RCT. In this study, called SURPASS-1, researchers tested three […]